Rusakiewicz, S., & Halama, N. (2017). NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. OncoImmunology, 6(1), . https://doi.org/10.1080/2162402X.2015.1137418
Chicago-Zitierstil (17. Ausg.)Rusakiewicz, Sylvie, und Niels Halama. "NKp30 Isoforms and NKp30 Ligands Are Predictive Biomarkers of Response to Imatinib Mesylate in Metastatic GIST Patients." OncoImmunology 6, no. 1 (2017). https://doi.org/10.1080/2162402X.2015.1137418.
MLA-Zitierstil (9. Ausg.)Rusakiewicz, Sylvie, und Niels Halama. "NKp30 Isoforms and NKp30 Ligands Are Predictive Biomarkers of Response to Imatinib Mesylate in Metastatic GIST Patients." OncoImmunology, vol. 6, no. 1, 2017, https://doi.org/10.1080/2162402X.2015.1137418.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.